DDInter875 DDInter1003
Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection. It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. The vaccine is prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, and 18, which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A has been found to be implicated in a variety of autoimmune diseases including Rheumatoid Arthritis and plaque psoriasis. Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing. Ixekizumab is comprised of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, and has a molecular weight of 146,158 Daltons for the protein backbone of the molecule. It is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Ixekizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc sulfate
Ixekizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lidocaine
Ixekizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Ixekizumab {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Ixekizumab {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Ixekizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine
Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Ixekizumab may lead to a major life threatening interaction when taken with Etanercept
Ixekizumab may lead to a major life threatening interaction when taken with Upadacitinib